Deferitrin
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530115

CAS#: 239101-33-8

Description: Deferitrin, also known as GT-56252, is an iron chelator potentially for the treatment of thelassemia and iron overload.


Chemical Structure

img
Deferitrin
CAS# 239101-33-8

Theoretical Analysis

MedKoo Cat#: 530115
Name: Deferitrin
CAS#: 239101-33-8
Chemical Formula: C11H11NO4S
Exact Mass: 253.04
Molecular Weight: 253.270
Elemental Analysis: C, 52.17; H, 4.38; N, 5.53; O, 25.27; S, 12.66

Price and Availability

Size Price Availability Quantity
5mg USD 495 2 Weeks
Bulk inquiry

Synonym: GT-56-252; GT 56 252; GT-56252; GT 56252; Deferitrin. GT-56-252

IUPAC/Chemical Name: 4,5-Dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazol-4-(S)-carboxylic acid

InChi Key: OEUUFNIKLCFNLN-LLVKDONJSA-N

InChi Code: InChI=1S/C11H11NO4S/c1-11(10(15)16)5-17-9(12-11)7-3-2-6(13)4-8(7)14/h2-4,13-14H,5H2,1H3,(H,15,16)/t11-/m1/s1

SMILES Code: O=C([C@]1(C)N=C(C2=CC=C(O)C=C2O)SC1)O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 253.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Donovan JM, Plone M, Dagher R, Bree M, Marquis J. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator. Ann N Y Acad Sci. 2005;1054:492-4. doi: 10.1196/annals.1345.071. PMID: 16339704.


2: Barton JC. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders. IDrugs. 2007 Apr;10(4):270-81. PMID: 17390251.


3: Barton JC. Drug evaluation: Deferitrin for iron overload disorders. IDrugs. 2007 Jul;10(7):480-90. PMID: 17642018.


4: Kontoghiorghes GJ. New chelation therapies and emerging chelating drugs for the treatment of iron overload. Expert Opin Emerg Drugs. 2006 Mar;11(1):1-5. doi: 10.1517/14728214.11.1.1. PMID: 16503822.


5: Rafati Rahimzadeh M, Rafati Rahimzadeh M, Kazemi S, Moghadamnia AR, Ghaemi Amiri M, Moghadamnia AA. Iron; Benefits or threatens (with emphasis on mechanism and treatment of its poisoning). Hum Exp Toxicol. 2023 Jan- Dec;42:9603271231192361. doi: 10.1177/09603271231192361. PMID: 37526177.


6: Kontoghiorghes GJ. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers. Hemoglobin. 2006;30(2):329-47. doi: 10.1080/03630260600642674. PMID: 16798657.


7: Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals. 2011 Apr;24(2):239-58. doi: 10.1007/s10534-010-9389-y. Epub 2010 Nov 20. PMID: 21103911; PMCID: PMC3329216.


8: Kontoghiorghes GJ, Eracleous E, Economides C, Kolnagou A. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations. Curr Med Chem. 2005;12(23):2663-81. doi: 10.2174/092986705774463003. PMID: 16305464.


9: Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005 Dec;57(4):547-83. doi: 10.1124/pr.57.4.2. PMID: 16382108.


10: Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S. Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues. J Med Chem. 2008 Jul 10;51(13):3913-23. doi: 10.1021/jm800154m. Epub 2008 Jun 6. PMID: 18533709; PMCID: PMC2759697.


11: Bergeron RJ, Wiegand J, Weimar WR, McManis JS, Smith RE, Abboud KA. Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier. Chirality. 2003 Aug;15(7):593-9. doi: 10.1002/chir.10248. PMID: 12840823.


12: Bergeron RJ, Wiegand J, McManis JS, McCosar BH, Weimar WR, Brittenham GM, Smith RE. Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues. J Med Chem. 1999 Jul 1;42(13):2432-40. doi: 10.1021/jm990058s. PMID: 10395484.


13: Bergeron RJ, Wiegand J, McManis JS, Vinson JR, Yao H, Bharti N, Rocca JR. (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity. J Med Chem. 2006 May 4;49(9):2772-83. doi: 10.1021/jm0508944. PMID: 16640338; PMCID: PMC2547084.